Skip to main navigation

Main Nav

About Us
Scientific Platform
Our Pipeline
Career Opportunities
Investors & Media

Press Releases

IR Nav

Overview
Press Releases
Events
Presentations
Annual Reports
Corporate Governance
SEC Filings
Stock Information
Analyst Coverage
FAQs
Email Alerts
Investor Contact

Shareholder Tools

Press Releases

Year

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 24, 2021

Gritstone Reports First Quarter 2021 Financial Results and Business Highlights

May 6, 2021

Gritstone Oncology Changes its Name to Gritstone bio to Reflect Expanded Therapeutic Focus

May 3, 2021

Gritstone Announces First Person Dosed with its Second-Generation COVID-19 Vaccine in Phase 1 Study Conducted and Supported by NIAID/IDCRC

March 29, 2021

Gritstone Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights

March 11, 2021

Gritstone Announces Promotions Within its Leadership Team

March 8, 2021

Gritstone to Present at the H.C. Wainwright Global Life Sciences Conference

March 2, 2021

Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure

February 1, 2021

Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine

January 20, 2021

Gritstone Advances Second Generation COVID-19 Vaccine “CORAL” Program with Support from NIAID; Program has Potential to Protect Against Mutant Variants of SARS-CoV-2

January 19, 2021

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Current page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

© 2022 Gritstone Bio |

Footer Links

Privacy Policy
Terms of Use
Contact

socials

Top